Table 3 Erythroid response, as assessed... | American Society of Hematology

Table 3

Erythroid response, as assessed by RBC-TI for ≥ 26 weeks or ≥ 8 weeks (double-blind phase; mITT and ITT populations)

	RBC-TI, n (%) [95% CI]
	Placebo	Lenalidomide 5 mg	Lenalidomide 10 mg
mITT population	n = 51	n = 47	n = 41
Protocol defined (≥ 26 wk)	3 (5.9) [1.2-16.2]	20 (42.6) [28.3-57.8]*	23 (56.1) [39.7-71.5]*
IWG 2000¹³ (≥ 8 wk)	4 (7.8) [2.2-18.9]	24 (51.1) [36.1-65.9]*	25 (61.0) [44.5-75.8]*
IWG 2006¹⁴ (≥ 8 wk)	3 (5.9) [1.2-16.2]	24 (51.1) [36.1-65.9]*	25 (61.0) [44.5-75.8]*
ITT population	n = 67	n = 69	n = 69
Protocol defined (≥ 26 wk)	4 (6.0) [1.7-14.6]	24 (34.8) [23.7-47.2]*	38 (55.1) [42.6-67.1]*
IWG 2000¹³ (≥ 8 wk)	5 (7.5) [2.5-16.6]	33 (47.8) [35.6-60.2]*	42 (60.9) [48.4-72.4]*
IWG 2006¹⁴ (≥ 8 wk)	4 (6.0) [1.7-14.6]	33 (47.8) [35.6-60.2]*	42 (60.9) [48.4-72.4]*

	RBC-TI, n (%) [95% CI]
	Placebo	Lenalidomide 5 mg	Lenalidomide 10 mg
mITT population	n = 51	n = 47	n = 41
Protocol defined (≥ 26 wk)	3 (5.9) [1.2-16.2]	20 (42.6) [28.3-57.8]*	23 (56.1) [39.7-71.5]*
IWG 2000¹³ (≥ 8 wk)	4 (7.8) [2.2-18.9]	24 (51.1) [36.1-65.9]*	25 (61.0) [44.5-75.8]*
IWG 2006¹⁴ (≥ 8 wk)	3 (5.9) [1.2-16.2]	24 (51.1) [36.1-65.9]*	25 (61.0) [44.5-75.8]*
ITT population	n = 67	n = 69	n = 69
Protocol defined (≥ 26 wk)	4 (6.0) [1.7-14.6]	24 (34.8) [23.7-47.2]*	38 (55.1) [42.6-67.1]*
IWG 2000¹³ (≥ 8 wk)	5 (7.5) [2.5-16.6]	33 (47.8) [35.6-60.2]*	42 (60.9) [48.4-72.4]*
IWG 2006¹⁴ (≥ 8 wk)	4 (6.0) [1.7-14.6]	33 (47.8) [35.6-60.2]*	42 (60.9) [48.4-72.4]*

P < .001 versus placebo.